Syneos Health Partners with Medable, Expanding Decentralized Solutions to Bring Clinical Trials Closer to the Patient
April 20 2021 - 8:00AM
Syneos Health® (Nasdaq:SYNH), the only fully integrated
biopharmaceutical solutions organization, and Medable, the leading
cloud platform for patient-centered drug development, today
announced a strategic partnership to bring clinical trials closer
to the patient. The partnership will deliver new decentralized
capabilities to Syneos Health with the aim of increasing clinical
trial diversity, while improving patient access and experiences to
transform biopharmaceutical product development.
Syneos Health will gain access to Medable’s digital platform
that reduces physician burden, simplifies the patient journey, and
collects previously difficult to obtain data to speed therapies to
patients across the clinical development lifecycle. The
collaboration will also deliver a fit-for-purpose decentralized
digital solution to Syneos Health customers tailored to the
specific attributes and requirements for conducting
non-interventional research.
“The demand for decentralized clinical trials has steadily
increased as sponsors search for innovative and meaningful ways to
drive efficiency, reduce cost and alleviate patient burden,” said
Maria Fotiu, Executive Vice President for Decentralized Solutions,
Syneos Health. “Our collaboration with Medable will identify
opportunities to capture data – real time – to better deliver
customized, decentralized solutions. When combined with our
Illingworth Research Group mobile research nursing capabilities, we
believe we’ll be able to engage more diverse populations and
increase access for patients who previously couldn’t participate in
clinical trials.”
Decentralized Solutions from Syneos Health combine deep
insights, agile technologies and operational excellence to
transform clinical trials. Medable’s patient-centered cloud
platform is a flexible and modular decentralized clinical trial
solution that scales to meet the unique needs of specific therapy
areas, indications and protocols. It delivers on-site and at-home
access on any web-enabled device utilizing Medable’s foundational
TeleVisit, TeleConsent, TeleCOA and remote patient monitoring
tools.
“We’re excited to work with Syneos Health to accelerate the
shift to patient-centric research,” said Alison Holland, Executive
General Manager of Digital and Decentralized Solutions for Medable.
“The decentralized model requires industry leaders working closely
together across an ecosystem to adopt new tools for decentralized
and hybrid studies. Combining Syneos Health’s deep experience with
our leading digital platform is a win-win-win for patients, sites
and sponsors.”
Medable will also now be part of the Syneos Health Dynamic
Assembly® network, an open ecosystem of preferred best-of-breed
data and technology collaborators committed to delivering
fit-for-purpose solutions designed to strategically address the
nuances of each customer engagement.
About Syneos HealthSyneos Health® (Nasdaq:SYNH)
is the only fully integrated biopharmaceutical solutions
organization. The Company, including a Contract Research
Organization (CRO) and Contract Commercial Organization (CCO), is
purpose-built to accelerate customer performance to address modern
market realities. We bring together approximately 25,000 clinical
and commercial minds with the ability to support customers in more
than 110 countries. Together we share insights, use the latest
technologies and apply advanced business practices to speed our
customers’ delivery of important therapies to patients.
To learn more about how we are Shortening the distance from lab
to life®, visit syneoshealth.com or subscribe to our podcast.
About MedableMedable is on a
mission to get effective therapies to patients faster by
transforming clinical drug development with disruptive
technologies. The company’s digital platform streamlines design,
recruitment, retention and data quality for decentralized trials,
replacing siloed systems with integrated digital tools, data and
interfaces to accelerate trial execution. Medable connects
patients, sites and clinical trial teams to improve patient access,
experience, and outcomes. Medable is a privately held,
venture-backed company headquartered in Palo Alto, California.
Syneos
Health Contacts: |
|
|
Investor Relations |
|
Press/Media |
Ronnie Speight |
|
Gary Gatyas |
Senior Vice President, Investor Relations |
|
Executive Director, External Communications |
+1 919 745 2745 |
|
+1 908 763 3428 |
Investor.Relations@syneoshealth.com |
|
gary.gatyas@syneoshealth.com |
|
|
|
Medable Contacts: |
|
|
Lisa Barbadora |
|
|
Big Valley Marketing for Medable |
|
|
+1 (610) 420-3413 |
|
|
media@medable.com |
|
|
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024